Researchers studied epidemiological, clinical, microbiological and laboratory data from patients with recurrent CDI due to relapse or reinfection over five years and compared them to a control group. Of 60 patients with recurrent CDI, 63.9 percent suffered from relapse and 36.1 percent from reinfection.
Researchers found previous antibiotic exposure was a risk factor for recurrent CDI. Patients suffering from relapse had previous antibiotic exposure more frequently than patients with reinfection.
They also found patients with reinfection suffered more frequently from chronic liver disease than relapse patients did.
Additionally, sporulation and germination frequency of the recurrent CDI group were higher than the control group.
More articles on healthcare quality:
Top 10 infection control stories, Sept. 18-22
6 children hospitalized in Wisconsin E coli outbreak
Flint’s Legionnaires’ outbreak likely killed more people than reported, says expert
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
